The disclosure provides methods for treating major depressive disorder in a human patient having moderate or severe anhedonia. The methods comprise administering to the patient in need thereof an effective amount of aticaprant, or a pharmaceutically acceptable salt thereof. In some embodiments, the patient had an inadequate response to other antidepressant therapy prior to treatment with aticaprant. In other embodiments, the other antidepressant therapy comprised a selective serotonin reuptake inhibitor (SSRI), serotonin-norepinephrine reuptake inhibitor (SNRI), or a combination thereof.

The disclosure provides methods for treating major depressive disorder in a human patient having moderate or severe anhedonia. The methods comprise administering to the patient in need thereof an effective amount of aticaprant, or a pharmaceutically acceptable salt thereof. In some embodiments, the patient had an inadequate response to other antidepressant therapy prior to treatment with aticaprant. In other embodiments, the other antidepressant therapy comprised a selective serotonin reuptake inhibitor (SSRI), serotonin-norepinephrine reuptake inhibitor (SNRI), or a combination thereof.

A method of treating or preventing vascular calcification in a patient by administering L-ascorbic acid or ascorbate to the patient and a pharmaceutical composition containing at least one statin and L-ascorbic acid or ascorbate in a dosage form that allows for the concomitant administering of the at least one statin and L-ascorbic acid or ascorbate to a patient.

A method of treating or preventing vascular calcification in a patient by administering L-ascorbic acid or ascorbate to the patient and a pharmaceutical composition containing at least one statin and L-ascorbic acid or ascorbate in a dosage form that allows for the concomitant administering of the at least one statin and L-ascorbic acid or ascorbate to a patient.

A method of treating or preventing vascular calcification in a patient by administering L-ascorbic acid or ascorbate to the patient and a pharmaceutical composition containing at least one statin and L-ascorbic acid or ascorbate in a dosage form that allows for the concomitant administering of the at least one statin and L-ascorbic acid or ascorbate to a patient.

The specification relates to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) for use in the treatment of cancer, wherein the EGFR TKI is administered in combination with a Smac mimetic.

The specification relates to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) for use in the treatment of cancer, wherein the EGFR TKI is administered in combination with a Smac mimetic.

There is provided a pharmaceutical formulation comprising an anticholinergic agent and a ternary solvent comprising 5% to 15% v/v glycol, 60% to 70% v/v alcohol and 5% to 20% v/v water. There is also provided a method of preparing the pharmaceutical formulation as disclosed herein, comprising the step of mixing the anticholinergic agent to a mixture containing alcohol, glycol, water, humectant and pH buffering agent at room temperature. There is also provided a method of inhibiting non-pathological body malodour in a mammal. There is also provided a method of treating apocrine secretion causing odour and reduction of microbial overgrowth in a mammalian subject, and uses of a pharmaceutical formulation.

There is provided a pharmaceutical formulation comprising an anticholinergic agent and a ternary solvent comprising 5% to 15% v/v glycol, 60% to 70% v/v alcohol and 5% to 20% v/v water. There is also provided a method of preparing the pharmaceutical formulation as disclosed herein, comprising the step of mixing the anticholinergic agent to a mixture containing alcohol, glycol, water, humectant and pH buffering agent at room temperature. There is also provided a method of inhibiting non-pathological body malodour in a mammal. There is also provided a method of treating apocrine secretion causing odour and reduction of microbial overgrowth in a mammalian subject, and uses of a pharmaceutical formulation.

In various embodiments, the present disclosure provides methods of diagnosing a need for peripheral arterial revascularization and/or reducing a need for peripheral arterial revascularization in a subject by administering to the subject a pharmaceutical composition comprising about 1 g to about 4 g of eicosapentaenoic acid ethyl ester or a derivative thereof.